ACTRN12607000223437
Withdrawn
Phase 1
A single centre open-label pilot study to evaluate the tolerability and safety of the Family C synthetic thermoplastic block copolymer implant as a clinically acceptable dermal filler material in healthy volunteers.
COSMETREND PTY LTD0 sites8 target enrollmentApril 27, 2007
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Tolerability and safety of a new synthetic soft tissue implant material for soft tissue augmentation in healthy volunteers.
- Sponsor
- COSMETREND PTY LTD
- Enrollment
- 8
- Status
- Withdrawn
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. In generally good health2\. Participants willing and able to comply with the requirements of the study3\. Participants willing and able to comply with the follow\-up requirements4\. Participants willing and able to give informed consent5\. Females must be post\-menopausal, surgically sterile or willing to use a medically acceptable form of birth control during the study. Males must be willing to use a medically acceptable form of birth control during the study.
Exclusion Criteria
- •1\. Participants who are pregnant, nursing or intend to become pregnant during the study period2\. Participants who were or are currently being treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids within the past 3 months. The use of stable doses of inhaled corticosteroids is acceptable.3\. Participants who were or are currently being treated with any topical Over The Counter (OTC) drug or prescription therapy on their torso within the past 3 months.4\. Participants with skin findings or disease in the proposed implant area that could confound the interpretation of the reactivity of the implant sites.5\. Participants with a history indicative of abnormal immune function (e.g. auto\-immune diseases, HIV, cancer \[other than non\-melanoma skin cancer], etc.)6\. Participants with known sensitivity to any of the Test Article materials.7\. Participants with severe allergies manifested by a history of anaphylaxis.8\. Participant is currently enrolled in an investigational drug or device study. 9\. Participant has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Pentosan Polysulfate Sodium (PPS) in subjects with mucopolysaccharidosis type I (MPS I)Mucopolysaccharidosis type I (MPS I)Metabolic and Endocrine - Metabolic disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12620000823976Paradigm Biopharmaceuticals Pty Ltd10
Active, not recruiting
Phase 1
A pilot study to assess the efficacy and safety of CBD oral solution in addition to standard treatment for pediatric subjects with Developmental and Epileptic EncephalopathyDevelopmental and Epileptic Encephalopathy (DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-001633-14-ITIRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA20
Completed
Phase 1
A single center, open-labeled, pilot study to evaluate the safety and efficacy of cardiac cycle-synchronized electrical lower limb muscle stimulation therapy for cardiovascular diseaseatent heart failure (NYHA class: II-III), ischemic heart disease (CCS class: II-III), peripheral artery disease (Fontaine class: II-IV), pulmonary artery hypertension (WHO class: II-III), and healthy adultJPRN-UMIN000026841Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine30
Not yet recruiting
Phase 1
Biocompatible & Biodegradable Polymeric Skin Grafts for WoundsHealth Condition 1: T758- Other specified effects of external causesCTRI/2020/11/029284SASTRA Deemed University
Recruiting
Phase 1
A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]CTIS2023-507137-24-00Institute Of Tropical Medicine78